Baidu
map

J Med Econ:草花粉皮下免疫疗法(SCIT)与舌下免疫治疗(SLIT)和对症治疗的成本效益比较分析

2018-01-02 AlexYang MedSci原创

虽然特异性免疫疗法(SIT)在治疗过敏性鼻炎方面与对症治疗相比性价比较高,然而在欧洲,相关SLIT与SCIT的比较研究仍旧缺乏。最近,有研究人员对草花粉过敏的SCIT与SLIT和对症治疗的成本和效益进行了比较,研究的地点为澳大利亚、瑞典和瑞士。研究发现,考虑到SCIT和SLIT的有效性,与药物对症治疗相比,SCIT和SLIT的准备工作是非常突出明显的。这两种治疗方法与额外的花费相关,但是当考虑到治

虽然特异性免疫疗法(SIT)在治疗过敏性鼻炎方面与对症治疗相比性价比较高,然而在欧洲,相关SLIT与SCIT的比较研究仍旧缺乏。最近,有研究人员对草花粉过敏的SCIT与SLIT和对症治疗的成本和效益进行了比较,研究的地点为澳大利亚、瑞典和瑞士。

研究发现,考虑到SCIT和SLIT的有效性,与药物对症治疗相比,SCIT和SLIT的准备工作是非常突出明显的。这两种治疗方法与额外的花费相关,但是当考虑到治疗效果的结果,这两种方法还是很有性价比的。SCIT与SLIT的一个直接比较显示在澳大利亚、瑞典和瑞士中,SCIT相比于SLIT的花费更低(1,368 €versus 2,012 €、2,229 €versus 2,547 €以及 1,901 €versus 2,220 €),以及更为优越的治疗效果(SCIT, 8.02 QALYs; SLIT, 7.98 QALYs;  对症治疗, 7.90 QALYs)。

最后,研究人员指出,患有过敏性鼻炎的病人,SIT为病人提供了比对症治疗更加经济有效的选择。当SCIT与SLIT比较时,SCIT在QALYs和花费方面更加优越,尤其是因为SCIT具有更高的病人服从性和更低的药物开销。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1988390, encodeId=ef951988390c1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Mar 22 16:22:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011064, encodeId=fe31201106474, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jul 13 21:22:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359864, encodeId=18ab1359864c6, content=<a href='/topic/show?id=8efa5402320' target=_blank style='color:#2F92EE;'>#成本效益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54023, encryptionId=8efa5402320, topicName=成本效益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396413, encodeId=37ee139641310, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608401, encodeId=3ad7160840192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738522, encodeId=d6e61e38522bc, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Oct 01 07:22:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274981, encodeId=5a4a2e498195, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 09:01:25 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274903, encodeId=d0912e490345, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed Jan 03 05:49:18 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1988390, encodeId=ef951988390c1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Mar 22 16:22:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011064, encodeId=fe31201106474, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jul 13 21:22:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359864, encodeId=18ab1359864c6, content=<a href='/topic/show?id=8efa5402320' target=_blank style='color:#2F92EE;'>#成本效益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54023, encryptionId=8efa5402320, topicName=成本效益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396413, encodeId=37ee139641310, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608401, encodeId=3ad7160840192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738522, encodeId=d6e61e38522bc, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Oct 01 07:22:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274981, encodeId=5a4a2e498195, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 09:01:25 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274903, encodeId=d0912e490345, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed Jan 03 05:49:18 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1988390, encodeId=ef951988390c1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Mar 22 16:22:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011064, encodeId=fe31201106474, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jul 13 21:22:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359864, encodeId=18ab1359864c6, content=<a href='/topic/show?id=8efa5402320' target=_blank style='color:#2F92EE;'>#成本效益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54023, encryptionId=8efa5402320, topicName=成本效益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396413, encodeId=37ee139641310, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608401, encodeId=3ad7160840192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738522, encodeId=d6e61e38522bc, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Oct 01 07:22:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274981, encodeId=5a4a2e498195, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 09:01:25 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274903, encodeId=d0912e490345, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed Jan 03 05:49:18 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1988390, encodeId=ef951988390c1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Mar 22 16:22:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011064, encodeId=fe31201106474, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jul 13 21:22:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359864, encodeId=18ab1359864c6, content=<a href='/topic/show?id=8efa5402320' target=_blank style='color:#2F92EE;'>#成本效益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54023, encryptionId=8efa5402320, topicName=成本效益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396413, encodeId=37ee139641310, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608401, encodeId=3ad7160840192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738522, encodeId=d6e61e38522bc, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Oct 01 07:22:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274981, encodeId=5a4a2e498195, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 09:01:25 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274903, encodeId=d0912e490345, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed Jan 03 05:49:18 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1988390, encodeId=ef951988390c1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Mar 22 16:22:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011064, encodeId=fe31201106474, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jul 13 21:22:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359864, encodeId=18ab1359864c6, content=<a href='/topic/show?id=8efa5402320' target=_blank style='color:#2F92EE;'>#成本效益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54023, encryptionId=8efa5402320, topicName=成本效益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396413, encodeId=37ee139641310, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608401, encodeId=3ad7160840192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738522, encodeId=d6e61e38522bc, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Oct 01 07:22:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274981, encodeId=5a4a2e498195, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 09:01:25 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274903, encodeId=d0912e490345, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed Jan 03 05:49:18 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1988390, encodeId=ef951988390c1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Mar 22 16:22:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011064, encodeId=fe31201106474, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jul 13 21:22:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359864, encodeId=18ab1359864c6, content=<a href='/topic/show?id=8efa5402320' target=_blank style='color:#2F92EE;'>#成本效益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54023, encryptionId=8efa5402320, topicName=成本效益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396413, encodeId=37ee139641310, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608401, encodeId=3ad7160840192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738522, encodeId=d6e61e38522bc, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Oct 01 07:22:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274981, encodeId=5a4a2e498195, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 09:01:25 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274903, encodeId=d0912e490345, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed Jan 03 05:49:18 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1988390, encodeId=ef951988390c1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Mar 22 16:22:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011064, encodeId=fe31201106474, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jul 13 21:22:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359864, encodeId=18ab1359864c6, content=<a href='/topic/show?id=8efa5402320' target=_blank style='color:#2F92EE;'>#成本效益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54023, encryptionId=8efa5402320, topicName=成本效益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396413, encodeId=37ee139641310, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608401, encodeId=3ad7160840192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738522, encodeId=d6e61e38522bc, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Oct 01 07:22:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274981, encodeId=5a4a2e498195, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 09:01:25 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274903, encodeId=d0912e490345, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed Jan 03 05:49:18 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
    2018-01-03 飛歌

    厉害了我的哥

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1988390, encodeId=ef951988390c1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Thu Mar 22 16:22:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011064, encodeId=fe31201106474, content=<a href='/topic/show?id=85ab46659e2' target=_blank style='color:#2F92EE;'>#对症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46659, encryptionId=85ab46659e2, topicName=对症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Jul 13 21:22:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359864, encodeId=18ab1359864c6, content=<a href='/topic/show?id=8efa5402320' target=_blank style='color:#2F92EE;'>#成本效益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54023, encryptionId=8efa5402320, topicName=成本效益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396413, encodeId=37ee139641310, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608401, encodeId=3ad7160840192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 04 11:22:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738522, encodeId=d6e61e38522bc, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Mon Oct 01 07:22:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274981, encodeId=5a4a2e498195, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 09:01:25 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274903, encodeId=d0912e490345, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Wed Jan 03 05:49:18 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
    2018-01-03 wzb521zf

    一起学习学习

    0

相关资讯

Allergol Int:TO-204在日本病人舌下免疫治疗的长期安全性分析

最近,研究人员进行了一个多中心、开放性标签临床试验,来评估TO-204舌下免疫治疗的长期安全性,TO-204是一种标准化的屋尘螨(HDM)过敏原提取物。研究参与的人员为年龄在5-65岁的日本患者,他们具有HDM诱导的过敏性鼻炎(AR)、过敏性支气管哮喘(BA)或者两种病都有。TO-204依照剂量滴定方案,维持剂量由之前定义的准则进行。治疗进行的周期为52周,并且那些愿意继续进行治疗的病人在接受另外

盘点:近期过敏性鼻炎研究进展盘点

过敏性鼻炎主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。其发生的必要条件有特异性抗原即引起机体免疫反应的物质、特应性个体、特异性抗原与特应型个体二者相遇。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】Clin Immunol:过敏性鼻炎患者对屋尘螨增

Arch Immunol Ther Exp (Warsz):过敏性鼻炎儿童中的外周血调节性T细胞变化分析

关于在小儿过敏性疾病中调节性T(Treg)细胞的研究,尤其是关于过敏性鼻炎(AR)的非常少,距离清晰的了解还很远。最近,有研究人员评估了CD4+CD25+Foxp3+ (CD4+Tregs) 和CD8+CD25+highFoxp3+ (CD8+Tregs) 调节性T细胞在AR儿童外周血中的频率情况。研究包括了60名AR儿童和40名健康儿童的新鲜全血样本。研究人员通过流式细胞仪检测了CD4+ 和CD

Clin Transl Allergy:屋尘螨皮下免疫治疗在老年过敏性鼻炎患者中的疗效和安全性证据

过敏原特异性免疫疗法(AIT)在老年病人中是具有争议的,并且到目前为止在该人群中能够支持该种疗法安全性和疗效方面的证据依据很少。最近,有研究人员评估了屋尘螨过敏原AIT疗法在年龄大于65岁且患有过敏性鼻炎(AR)和对屋尘螨过敏的患者中的疗效和安全性。研究包括了58名只对屋尘螨敏感的老年病人,并且被随机分配到数目匹配的两个平行小组中,并且进行了如下的干预:利用PURETHAL螨虫或者安慰剂进行为期2

Allergol Int:在健康和哮喘患者中,血清骨膜蛋白与身体质量指数和过敏性鼻炎相关

许多研究在哮喘患者中尝试鉴定了与血清骨膜蛋白水平相关的因素。然而,这些研究的结果主要基于对具有高嗜酸性粒细胞数目患者的研究,这也许会对与血清骨膜蛋白水平相关的其他因素的鉴定造成干扰。最近,有研究人员确定了在健康受试者中,与血清骨膜蛋白水平相关的因素。研究人员同样在哮喘患者中评估了一些因素,从而认知它们在哮喘中的作用。研究测量了230健康受试者的血清骨膜蛋白水平。感兴趣的临床因素包括了身体质量指数(

Allergy Asthma Immunol Res:过敏性鼻炎的中药治疗研究

中草药(CHM)在中国被广泛的应用于过敏性鼻炎(AR)的治疗。然而,一些研究关于中草药治疗过敏性鼻炎的疗效,产生了相互矛盾的结果。最近,有研究人员进行那个了随机临床试验(RCTs)的元分析来评估CHM的相关疗效。研究人员就在AR病人的治疗中,利用RCTs比较CHM疗效和安慰剂方面,系统性的查询了到2017年3月份的PubMed、Medine和Springer电子数据库。总的鼻症状和生活质量通过混样

Baidu
map
Baidu
map
Baidu
map